Mota loda dw
The sequences for the primers were as follows: Cox-2, forward: 5′-TGGACAGGGAGGATTTTGAG-3′, reverse: 5′-AGGCTGTGCCTTCCTACAGA-3′; E-cadherin, forward: 5′-ACGTCGTAATCACCACACTGA-3′, reverse: 5′-TTCGTCACTGCTACGTGTAGAA-3′; Cytokeratin 19, forward: 5′-GCGGGACAAGATTCTTGGTG-3′, reverse: 5′-CTTCAGGCCTTCGATCTGCAT-3′; Vimentin, forward: 5′-CTTCGCCAACTACATCGACA-3′, reverse: 5′-GCTTCAACGGCAAAGTTCTC-3′; N-cadherin, forward: 5′-ACAGTGGCCACCTACAAAGG-3′, reverse: 5′-CCGAGATGGGGTTGATAATG-3′; SNAIL, forward: 5-TCGTCCTTCTCCTCTACTTC-3′, reverse: 5-TTCCTTGTTGCAGTATTTGC-3′; Slug, forward: 5′-TCGGACCCACACATTACC-3′, reverse: 5′-CCGAGATGGGGTTGATAATG-3′; Twist, forward: 5′-AGCTGAGCAAGATTCAGACCCTC-3′, reverse: 5′-CCGTCTGGGAATCACTGT C-3′; Zeb 1, forward: 5′-CTGAAGAGGACCAGAGGCAG-3′, reverse: 5′-CCCAGAACTGCGTCACATGTC-3′; and β-actin, forward: 5′-GGACTTCGAGCAAGAGATGG-3′, reverse: 5-AGCACTGTGTTGGCGTACAG-3′.
Within the clinical drug concentrations, only etodolac showed the in vitro growth inhibition in T24 not in the other cell lines.
Etodolac at clinical doses exhibited induced in vitro and in vivo anti-tumour effects and reversal effect of EMT in T24.
These results suggest that etodolac is a good candidate for an anti-tumour or chemopreventive reagent for high-grade bladder cancer.
Mc Conkey et al (2009) measured these EMT markers in a panel of 20 human urothelial TCC cell lines and a set of 114 primary urothelial tumours, and observed a strong inverse correlation between the expression of E-cadherin and those of Zeb-1, Zeb-2 and vimentin.
They found that the expression of the mesenchymal markers was confined to the muscle-invasive tumour.